|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1989-7-18
|
|
pubmed:abstractText |
To evaluate the toxicity, effects on immune function, antitumor effects, antiretroviral effects, and pharmacokinetics of zidovudine therapy in patients with early human immunodeficiency virus (HIV) infection and Kaposi sarcoma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0003-4819
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
111
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
41-50
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:2735626-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:2735626-Adult,
pubmed-meshheading:2735626-Anemia,
pubmed-meshheading:2735626-Double-Blind Method,
pubmed-meshheading:2735626-Drug Evaluation,
pubmed-meshheading:2735626-Granulocytes,
pubmed-meshheading:2735626-HIV,
pubmed-meshheading:2735626-Humans,
pubmed-meshheading:2735626-Leukocyte Count,
pubmed-meshheading:2735626-Male,
pubmed-meshheading:2735626-Middle Aged,
pubmed-meshheading:2735626-Prospective Studies,
pubmed-meshheading:2735626-Random Allocation,
pubmed-meshheading:2735626-Sarcoma, Kaposi,
pubmed-meshheading:2735626-Zidovudine
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial.
|
|
pubmed:affiliation |
National Institutes of Health, Bethesda, Maryland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
